ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative7.02 M11.29 M11.37 M10.34 M10.53 M43.53 MRicerca e sviluppo2.91 M5.01 M6.88 M7.99 M9.37 M29.25 MReddito operativo3.04 M642 K2.59 M-388 K-2.18 M660 KProventi non operativi, Totale84 K310 K425 K440 K451 K1.63 MOneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari137 K306 K459 K473 K458 K1.7 MEntrate/uscite straordinarie-53 K4 000-34 K-33 K-7 000-70 KUtile al lordo delle imposte-3.4 M1.26 M3.21 M375 K-1.33 M3.51 MQuota di utile——————Imposte0195 K508 K-455 K565 K813 KInteressi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate-3.4 M1.07 M2.7 M830 K-1.9 M2.7 MAttività cessate——————Utile netto-3.4 M1.07 M2.7 M830 K-1.9 M2.7 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-3.4 M1.07 M2.7 M830 K-1.9 M2.7 MUtile base per azione (EPS base)-0.060.030.080.02-0.050.08Utile diluito per azione (EPS diluito)-0.060.030.070.02-0.050.07Numero medio di azioni ordinarie in circolazione28.51 M34.64 M35.79 M36.38 M35.82 M142.63 MAzioni diluite in circolazione28.51 M39.51 M40.26 M40.06 M39.92 M159.75 MEBITDA2.94 M685 K2.69 M-288 K-2.19 M898 KEBIT3.04 M642 K2.59 M-388 K-2.18 M660 KCosto del fatturato2.13 M2.85 M3.32 M2.62 M3.01 M11.8 MAltri costi del venduto——————Ammortamento e svalutazione (liquidità)-95 K43 K100 K100 K-5 000238 K
Delcath Systems Inc
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.